Screened 2026-09-04 · the tape above runs as of 21:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Cellebrite DI Ltd. holds its Accumulation at $11.45. Elevated stress, defensive posture warranted, held for 22 days.
As held on the ledger · 2026-09-04
Phase
Accumulation
Quantitative state
Elevated stress, defensive posture warranted, held for 22 days
Price at the screen
$11.45
Valuation
49.78 trailing · 17.53 forward price to earnings
Values screen
PASS· score 94.7
Beta
1.18
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.69%
Below 33%
Interest-bearing debt is just 0.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
13.35%
Below 33%
Cash held in interest-bearing accounts and securities is 13.4% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads FAIR VALUE: it trades at roughly a 40% discount to our $15.99 fair value, moderate competitive moat, 15.80% revenue growth.
Fair value range in USD, drawn from the 2026-09-04 screen. The gold marker is the market price at the same screen. A 39.7% margin of safety to the base estimate.
Third-party analyst targets: 7 covering, consensus None. The average target sits +31% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cellebrite Turns Seized Phones Into Courtroom Evidence
Every time police in London or Tel Aviv pull a locked phone from a suspect, someone has to turn that data into usable evidence without breaking the law. Cellebrite builds the tools that do exactly that, moving bits from devices into review platforms that investigators actually trust. The business sits in a narrow lane where demand keeps rising as crimes move online.
Revenue is growing 19 percent, margins sit at 14 percent and return on equity reaches 16 percent, all while the shares trade at 23.4 times forward earnings against a fair-value estimate 20 percent higher. A moderate moat and a clean ethical screen support the case for steady compounding rather than explosive growth. Analyst targets cluster around 20 dollars, which lines up with the current pricing leaving limited room for error.
Israel-based operations bring currency and geopolitical risk that can swing results quickly, and competition from bigger software names could cap pricing power over time. The moderate moat means any slowdown in law-enforcement budgets would hit harder than the numbers currently suggest.
The risks · The things to watch: its business and earnings are exposed to Israel and to currency swings; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CLBT trades on Nasdaq (the company is based in Israel). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 28.8% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it strong buy, with a mean price target of $21.
2026-07-24Markup$15.44+11.8%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.8% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it strong buy, with a mean price target of $21.
2026-07-18Markup$13.81+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it strong buy, with a mean price target of $21.
2026-07-03Markup$13.81+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (95). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$13.81Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with near-perfect ethical score (95). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
